These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

520 related items for PubMed ID: 26885621

  • 1. Novel potential serological prostate cancer biomarkers using CT100+ cancer antigen microarray platform in a multi-cultural South African cohort.
    Adeola HA, Smith M, Kaestner L, Blackburn JM, Zerbini LF.
    Oncotarget; 2016 Mar 22; 7(12):13945-64. PubMed ID: 26885621
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Autoantibody signatures as biomarkers to distinguish prostate cancer from benign prostatic hyperplasia in patients with increased serum prostate specific antigen.
    O'Rourke DJ, DiJohnson DA, Caiazzo RJ, Nelson JC, Ure D, O'Leary MP, Richie JP, Liu BC.
    Clin Chim Acta; 2012 Mar 22; 413(5-6):561-7. PubMed ID: 22146597
    [Abstract] [Full Text] [Related]

  • 5. Preferential autoimmune response in prostate cancer to cyclin B1 in a panel of tumor-associated antigens.
    Dai L, Li J, Ortega R, Qian W, Casiano CA, Zhang JY.
    J Immunol Res; 2014 Mar 22; 2014():827827. PubMed ID: 24860838
    [Abstract] [Full Text] [Related]

  • 6. Differential blood-based diagnosis between benign prostatic hyperplasia and prostate cancer: miRNA as source for biomarkers independent of PSA level, Gleason score, or TNM status.
    Leidinger P, Hart M, Backes C, Rheinheimer S, Keck B, Wullich B, Keller A, Meese E.
    Tumour Biol; 2016 Aug 22; 37(8):10177-85. PubMed ID: 26831660
    [Abstract] [Full Text] [Related]

  • 7. Diagnostic and prognostic value of serum miR-15a and miR-16-1 expression among egyptian patients with prostate cancer.
    Zidan HE, Abdul-Maksoud RS, Elsayed WSH, Desoky EAM.
    IUBMB Life; 2018 May 22; 70(5):437-444. PubMed ID: 29522280
    [Abstract] [Full Text] [Related]

  • 8. Discovery of novel candidate urinary protein biomarkers for prostate cancer in a multiethnic cohort of South African patients via label-free mass spectrometry.
    Adeola HA, Soares NC, Paccez JD, Kaestner L, Blackburn JM, Zerbini LF.
    Proteomics Clin Appl; 2015 Jun 22; 9(5-6):597-609. PubMed ID: 25708745
    [Abstract] [Full Text] [Related]

  • 9. A novel urinary mRNA signature using the droplet digital polymerase chain reaction platform improves discrimination between prostate cancer and benign prostatic hyperplasia within the prostate-specific antigen gray zone.
    Kang HW, Lee HY, Byun YJ, Jeong P, Yoon JS, Kim DH, Kim WT, Kim YJ, Lee SC, Yun SJ, Kim WJ.
    Investig Clin Urol; 2020 Jul 22; 61(4):411-418. PubMed ID: 32665998
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Identification of microRNAs differentially expressed in prostatic secretions of patients with prostate cancer.
    Guzel E, Karatas OF, Semercioz A, Ekici S, Aykan S, Yentur S, Creighton CJ, Ittmann M, Ozen M.
    Int J Cancer; 2015 Feb 15; 136(4):875-9. PubMed ID: 24976077
    [Abstract] [Full Text] [Related]

  • 13. Urinary Polyamines: A Pilot Study on Their Roles as Prostate Cancer Detection Biomarkers.
    Tsoi TH, Chan CF, Chan WL, Chiu KF, Wong WT, Ng CF, Wong KL.
    PLoS One; 2016 Feb 15; 11(9):e0162217. PubMed ID: 27598335
    [Abstract] [Full Text] [Related]

  • 14. [Biomarkers of prostate cancer and potential for using ace produced in prostate gland for diagnosis of prostate cancer and benign prostatic hyperplasia].
    Kamalov AA, Samokhodskaya LM, Karpov VK, Okhobotov DA, Mamedov VN.
    Urologiia; 2019 Jun 15; (2):73-81. PubMed ID: 31162906
    [Abstract] [Full Text] [Related]

  • 15. The prostate cancer immunome: In silico functional analysis of antigenic proteins from microarray profiling with IgG.
    Luna-Coronell JA, Vierlinger K, Gamperl M, Hofbauer J, Berger I, Weinhäusel A.
    Proteomics; 2016 Apr 15; 16(8):1204-14. PubMed ID: 27089054
    [Abstract] [Full Text] [Related]

  • 16. Expression of PCA3 and PSA genes as a biomarker for differential diagnosis of nodular hyperplasia and prostate cancer.
    Coelho FF, Guimarães FL, Cabral WL, Salles PG, Mateo EC, Nogueira e Nogueira LM, Fonseca CE, Gomes KB.
    Genet Mol Res; 2015 Oct 28; 14(4):13519-31. PubMed ID: 26535666
    [Abstract] [Full Text] [Related]

  • 17. Prostate stem cell antigen (PSCA) mRNA expression in peripheral blood in patients with benign prostatic hyperplasia and/or prostate cancer.
    Fawzy MS, Mohamed RH, Elfayoumi AR.
    Med Oncol; 2015 Mar 28; 32(3):74. PubMed ID: 25698533
    [Abstract] [Full Text] [Related]

  • 18. Classification analyses for prostate cancer, benign prostate hyperplasia and healthy subjects by SERS-based immunoassay of multiple tumour markers.
    Zhou L, Liu Y, Wang F, Jia Z, Zhou J, Jiang T, Petti L, Chen Y, Xiong Q, Wang X.
    Talanta; 2018 Oct 01; 188():238-244. PubMed ID: 30029370
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 26.